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Abstract
The vast majority of people living with human immunodeficiency virus type 1 (HIV-1) have pain syndrome, which has a
significant impact on their quality of life. The underlying causes of HIV-1-associated pain are not likely attributable to direct
viral infection of the nervous system due to the lack of evidence of neuronal infection by HIV-1. However, HIV-1 proteins are
possibly involved as they have been implicated in neuronal damage and death. The current study assesses the direct effects
of HIV-1 Tat, one of potent neurotoxic viral proteins released from HIV-1-infected cells, on the excitability and survival of rat
primary dorsal root ganglion (DRG) neurons. We demonstrated that HIV-1 Tat triggered rapid and sustained enhancement
of the excitability of small-diameter rat primary DRG neurons, which was accompanied by marked reductions in the
rheobase and resting membrane potential (RMP), and an increase in the resistance at threshold (RTh). Such Tat-induced DRG
hyperexcitability may be a consequence of the inhibition of cyclin-dependent kinase 5 (Cdk5) activity. Tat rapidly inhibited
Cdk5 kinase activity and mRNA production, and roscovitine, a well-known Cdk5 inhibitor, induced a very similar pattern of
DRG hyperexcitability. Indeed, pre-application of Tat prevented roscovitine from having additional effects on the RMP and
action potentials (APs) of DRGs. However, Tat-mediated actions on the rheobase and RTh were accelerated by roscovitine.
These results suggest that Tat-mediated changes in DRG excitability are partly facilitated by Cdk5 inhibition. In addition,
Cdk5 is most abundant in DRG neurons and participates in the regulation of pain signaling. We also demonstrated that HIV-
1 Tat markedly induced apoptosis of primary DRG neurons after exposure for longer than 48 h. Together, this work indicates
that HIV-1 proteins are capable of producing pain signaling through direct actions on excitability and survival of sensory
neurons.
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Introduction
Globally, the HIV-1 (the causative agent of AIDS) pandemic
has claimed over 25 million lives with 33.4 million people
currently infected (2009 AIDS Epidemic Update by UNAIDS/
WHO, www.unaids.org). The number of people living with HIV-1
worldwide continues to grow because of high rates of new
infections and the beneficial impact of antiretroviral therapy
(ART), also known as the highly active antiretroviral therapy
(HAART). The vast majority (up to 90%) of these individuals
living with HIV-1/AIDS have pain syndrome that has a
significant impact on their psychological wellbeing and quality of
life [1,2,3,4,5,6,7,8,9,10,11,12]. Pain occurs at all stages of HIV-1
infection, although its severity and frequency are correlated with
disease progression [1,13]. Studies have reported that non-white
patients (the majority of the HIV-1-infected people worldwide) are
more likely than Caucasians to have uncontrolled pain when dying
of HIV-1/AIDS [1,14]. The most common pain syndromes in
HIV-1/AIDS patients include painful peripheral neuropathies,
headache, oral and pharyngeal pain, abdominal pain, chest pain,
arthralgias and myalgias, painful dermatological conditions, and
pain caused by HIV-1/AIDS-related malignancies such as
Kaposi’s sarcoma [15,16]. Given that patients with HIV-1/AIDS
live longer with their illness in the era of HAART, which has
successfully transformed HIV-1/AIDS from a death sentence to a
chronic yet manageable disease for most individuals, management
of symptoms including pain has been identified as one of the top
priorities for HIV-1/AIDS clinical and translational research.
However, pain is often under-assessed and undertreated in people
with HIV-1/AIDS illness, and little progress has been made to
address the issues of pain etiologies that are the key for pain
management and improvement of the quality of life.
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24412The pain in HIV-1/AIDS patients is usually divided into two
categories: neuropathic and nociceptive [1], and has been
suggested to be associated with (1) direct neurotoxic effects of
viral components on neurons in both central and peripheral
nervous systems, (2) immune dysregulation leading to inflamma-
tory changes, opportunistic infections and tumors, and (3) drug-
related adverse effects [1,2,16]. HIV-1 directly infects the
perivascular macrophages [17,18], resident microglia [19] and
astrocytes [20], but not neurons in the central nervous system
(CNS). While evidence of neuronal infection by HIV-1 is lacking,
viral proteins are likely to be directly involved in neuronal damage
and death. HIV-1 encodes a total of nine viral proteins including
three structural proteins (Env, Pol, and Gag), two essential
regulatory proteins (Tat and Rev), and four accessory proteins
(Vif, Vpr, Vpu, and Nef). These viral proteins have been
extensively studied for their role in HIV-1-associated CNS
neuropathy. To date, five of these proteins including Env, Tat,
Vpr, Nef, and Rev have been identified as potent neurotoxic viral
proteins in that they directly induce neuronal cell death
[17,18,19,20,21,22,23,24,25,26]. These proteins are implicated
in HIV-1-associated CNS pathologies such as mild to severe
cognitive impairments (HIV-1-associated dementia) and enceph-
alitis (NeuroAIDS) [17,18,19,20,21,22,23,24,25,26]. However, the
role of these proteins in the pathogenesis of HIV-1-associated pain
has been largely unexplored. Recent studies have shown that Env
and Vpr exert neurotoxic activities on peripheral sensory neurons
(pain-sensing neurons). Injection of Env into the spinal intrathecal
space of rats causes marked pain-like behavior [27,28,29,30,31],
and Vpr enhances excitability of dorsal root ganglion (DRG)
neurons [32]. These results suggest that HIV-1 neurotoxic proteins
have direct effects on peripheral nerves, and may be causative
factors in the generation of neuropathic pain in HIV-1-infected
individuals. Notably, HIV-1 gp120 (surface unit of Env) appears to
bind to the surface of rat DRG neurons, probably via the
chemokine receptors CXCR4, CCR5 or/and others [33], and Tat
appears to exert its neurotoxic activity via binding to the NMDA
(N-methyl D-aspartate) receptor and the low-density lipoprotein
receptor-related protein (LRP) [34,35,36,37], whereas evidence of
Vpr, Nef, or Rev binding to surface receptor(s) of neurons is
lacking.
The current study assesses the direct effects of HIV-1 Tat
protein on excitability and survival of rat primary DRG neurons.
We demonstrated that Tat directly triggered rapid and sustained
enhancement of the excitability of the small-diameter DRG
neurons, probably by inhibiting kinase activity and mRNA
production of Cdk5, a proline-directed serine/threonine kinase
that has recently emerged as a key kinase in regulation of pain
signaling in sensory neurons [38,39,40]. HIV-1 Tat also markedly
reduced p35 (a Cdk5 activator) mRNA production and induced
apoptosis of DRG neurons. These results indicate that Tat are
capable of producing pain signaling through direct actions on
excitability and survival of sensory neurons.
Materials and Methods
HIV-1 Tat and Gag proteins
Recombinant HIV-1IIIB Tat and recombinant HIV-1IIIB Gag
(p24) were purchased from the Advanced Biotechnologies
(Columbia, MD). These proteins were produced using the
baculovirus expression system and purified by immunoaffinity
chromatography. The proteins were reconstituted at appropriate
concentrations in phosphate buffered saline (PBS), and then stored
at 280uC until use. An aliquot of Tat protein was heat-inactivated
by incubation at 85uC for 30 min as previously described [41].
The heat-inactivated Tat protein has been extensively used as a
negative control for bioactive Tat [41,42,43] and was used as a
control for the DRG excitability experiments in this study.
Isolation and culture of adult rat sensory neurons
Primary DRG neurons were isolated from young adult male
Sprague Dawley rats using procedures described in our previous
report [44]. Briefly, young adult Sprague–Dawley rats (100
2150 g) (Charles River Laboratories, Wilmington, MA) were
sacrificed by carbon dioxide narcosis according to the institutional
protocol (the animal care and use protocol #3282 approved by the
Institutional Animal Care and Use Committee of the Indiana
University School of Medicine). DRG tissues were dissected from
all spinal segments and were then collected in a culture dish filled
with sterilized Puck’s solution (without Ca
2+ and Mg
2+). The DRG
tissues were transferred to a conical tube with Ham’s F-12 media
(Mediatech, Manassas, VA) containing papain (20 U/ml) (Sigma
Chemical, St. Louis, MO) and then incubated for 15 min at 37uC,
followed by incubation in 1 mg/ml collagenase IA (Sigma
Chemical, St. Louis, MO) and 2.5 mg/ml dispase (Sigma
Chemical, St. Louis, MO) for 10 min. The DRG neurons were
pelleted and were then resuspended in F-12 media supplemented
with 30 ng/ml nerve growth factor (NGF, Invitrogen, Carlsbad,
CA). The cells were mechanically dissociated with reduced bore
pipettes until all obvious chunks of tissues were gone. The isolated
cells were plated onto plastic coverslips or 6-well plates pre-coated
with poly-D-lysine (100 mg/ml) and laminin (5 mg/ml), and were
then cultured for 24–36 h at 37uC in a humidified atmosphere
with 3% CO2. The cells were used for electrophysiological studies
or others.
Electrophysiology
Patch-clamp recordings were made at room temperature (23uC)
using the whole-cell patch-clamp technique as described in our
previous report [44]. Briefly, a coverslip with DRG neurons was
placed in a recording chamber (Warner Instrument, Hamden,
CT) where DRG neurons were bathed in normal Ringers solution
of the following composition: 140 mM NaCl, 5 mM KCl, 2 mM
CaCl2, 1 mM MgCl2, 10 mM HEPES, and 10 mM glucose (pH
at 7.4). Recording pipettes were pulled from disposable borosil-
icate glass tubing and typically had resistances of 2–5 MV when
filled with the following solution: 140 mM KCl, 5 mM MgCl2,
4 mM ATP, 0.3 mM GTP, 2.5 mM CaCl2, 5 mM EGTA
(calculated free Ca
2+ concentration of ,100 nM), and 10 mM
HEPES, at pH 7.3 with KOH. Whole cell voltages were recorded
with an Axopatch 200B amplifier (Molecular Devices, Sunnyvale,
CA). Data were acquired and analyzed using pCLAMP 8.2 or
pCLAMP 9.0.2 (Molecular Devices, Sunnyvale, CA). The whole-
cell recording configuration was established in normal Ringers
solution. After establishing the whole-cell configuration, both the
capacitance and resistance were compensated by ,80%. To assess
the excitability, the DRG neurons were held at their resting
potentials (range between 242 and 262 mV), and a ramp of
depolarizing current (1 s in duration) was applied to the neuron
wherein the amplitude of the ramp was adjusted to produce three
to four action potentials (APs) under control conditions. The
stimulation amplitude then remained constant throughout the
recording period for each individual neuron. The number of APs
was recorded at 2, 4, 6, 10, and 15 min time points after exposure
to the test agent using the same ramp amplitude. These recordings
were sampled at 1–2 kHz using pClamp 8.0 (Axon Instruments,
Weatherford, TX). To test whether the impact of Tat on DRG
excitability is affected by roscovitine, Tat (20 mM) was focally
applied to an individual DRG neuron to assess its actions over a
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roscovitine by external perfusion of the recording chamber. At the
end of each recording, 100 nM capsaicin (a neurotoxin) was
focally applied to the neuron for ,2 seconds. If the neuron
depolarized by at least 5 mV and generated APs, then it was
judged to be capsaicin sensitive. Capsaicin has been used to
distinguish capsaicin-sensitive sensory neurons that are believed to
transmit nociceptive information [45,46]. The electrophysiological
results reported below were obtained from only capsaicin-sensitive
small-diameter DRG neurons.
Cdk5 kinase assay
Cdk5 kinase assays were conducted as described in our previous
report [47,48]. Briefly, DRG neurons treated with 20 mM of HIV-
1 Tat or Gag from 15 min to 1 h were rinsed twice with cold PBS
and lysed in 1% NP-40 lysis buffer (1% NP-40, 20 mM Tris, pH
8.0, 150 mM NaCl, 1 mM PMSF, 10 mg/ml leupeptin, and
10 mg/ml aprotinin) and cleared by centrifugation at 10,000 rpm
for 10 min at 4uC. Cleared lysates were mixed with Cdk5 antibody
and protein A Sepharose beads (Sigma Chemical, St. Louis, MO)
and incubated at 4uC for 2 h. Immune complexes were washed
twice with 1% NP-40 lysis buffer and twice with kinase buffer
(50 mM Tris, pH 8.0, 20 mM MgCl2), and were then subjected to
in vitro Cdk5 kinase assays using [c-
32P]ATP and 5 mg of Cdk5
substrate peptide (KHHKSPKHR) in a final volume of 30 ml
buffered at pH 8.0 containing 50 mM Tris and 20 mM MgCl2 at
30uC. After 20 min of incubation, the reactions were terminated
by spotting 25 ml of the reaction volume onto p81 phosphocellu-
lose disks (Whatman, Clifton, NJ) and immersing in 100 ml of
10% acetic acid for 30 min, followed by three washings in 0.5%
phosphoric acid (5 min each) and finally rinsing with acetone. The
radioactivity was measured in a liquid scintillation counter. DRG
neurons treated with PBS were included in each experiment as a
control for obtaining baseline data.
Semi-quantitative RT-PCR and real-time quantitative RT-
PCR (qPCR)
Semi-quantitative RT-PCR and real-time quantitative RT-
PCR (qPCR) studies were used to measure changes of Cdk5 and
p35 mRNA abundance in DRG neurons in response to HIV-1
Tat, Gag or PBS treatment. Total RNA was isolated from DRG
neurons after exposure to HIV-1 Tat, Gag or PBS using RNeasy
Micro Kit (QIAGEN, Valencia, CA) according to the manufac-
turer’s protocol. Prior to RNA elution from an RNeasy column,
DNA removal was performed by on-column DNase digestion for
15 min at room temperature using RNase-Free Set (QIAGEN,
Valencia, CA). Total RNA (1 mg per sample) were reverse
transcribed into cDNA using the SuperScript First-Strand
Synthesis System and oligo(dT)12–18 oligodeoxynucleotide primer
(Invitrogen, Carlsbad, CA). Three plasmid constructs containing
partial rat Cdk5, p35, or the house-keeping gene glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) gene were generated and
used to establish standard curves in each real-time qPCR
performance for quantitative analysis of cDNA copy number.
RNA or plasmid DNA concentrations were determined using a
ND-1000 UV–vis Spectrophotometer (NanoDrop Technologies,
Wilmington, DE). The number of construct copies in the plasmid
solution was calculated, based on plasmid vector size (pCR2.1-
TOPO, Invitrogen, Carlsbad, CA) plus insert size of Cdk5, p35, or
rat GAPDH. A plasmid-based calibration curve was generated
with 10-fold serial dilutions of plasmid containing the Cdk5 or p35
gene fragment sequence; to control pipetting steps, three 10-fold
serial dilutions were prepared, and concentrations were checked
by real-time qPCR. For Cdk5 or p35, the quantification was linear
over a range of 10 to 10
7 starting plasmid copy numbers, and the
detection limit was ten copies per reaction. The rat house-keeping
gene GAPDH was used as an internal control for the
normalization of the amount of cDNA in each sample.
Real-timeqPCR was performed in a StepOnePlus Real-time PCR
System (Applied Biosystems, Foster City, CA). Each sample and
standard, including DRG neurons treated with HIV-1 Tat, Gag or
PBS control, was set up in triplicate containing 5 mlo f26 Sybr
Green Master Mix, 15 pmol each primer, and 50–100 ng sample
cDNA. PCR cycling conditions were 95 uC for 10 min, followed by
40 cycles of 95uCfor30s,55uCfor30s,and72uC for30 s, and then
a final extension step at 72 uCf o r1 0m i n .T h ef l u o r e s c e n c ei n t e n s i t y
of SYBR green was measured automatically during the annealing
steps. At the end of each run, a melting curve analysis was performed.
Experiments were performed with undiluted and 10-fold diluted
template cDNA in triplicate. The initial specimen cDNA was diluted
in concentrations corresponding to40,000cellequivalents/10 mlwi th
the number of cell equivalents calculated assuming that 6.6 ng of
cDNA was equivalent to 1 610
3 cells. Initially, RNA samples were
adjusted to the same concentrations and the same amount of
template was used for amplifying Cdk5 or rat GAPDH. The PCR
primers used were described previously [49]. Semi-quantitative
amplification was performed using the following primers: 5’-
GGCACCTACGGAACTGTGTT-39 (forward) and 59-CA-
CAATCTCAGGGTCCAGGT-39 (reverse) for rat cdk5, 59-
TGACCTGTCTGTACCTCTCC-39 (forward) and 5’-GCACA-
GAAAGTCATCAAAGCC-39 (reverse) for rat p35, and 59-GA-
CATGCCGCCTGGAGAAAC-39 (forward) and 59-AGCCCAG-
GATGCCCTTTAGT-39 (reverse) for rat GAPDH. For cdk5 real-
time qPCR, the primers used were: forward 59- AGCCTTTGG-
TATCCCAGTCC – 39, and reverse 59- TCCTCTTCAGCTGGT-
CATCC – 39. Primers for rat p35 semi-quantitative RT-PCR were
also used for p35 real-time qPCR.
Flow cytometric analysis
Flow cytometric analysis was performed using a FACSCalibur
(BD Biosciences, San Jose, CA) after staining by standard methods,
and all data were analyzed using FlowJo software (Tree Star, San
Carlos, CA). Apoptotic cell death and cellular apoptosis were
determined by staining with annexin-V
FITC and propidium iodide
(PI) from the annexin-V-FLUOS staining kit (Roche Applied
Science, Indianapolis, IN) according to the manufacturer’s
protocol. Rat primary DRG neurons seeded in 6-well cell culture
plates were incubated with 20 mM of HIV-1 Tat, Gag, or PBS for
30 min to 72 h. After incubation, the plates were chilled on ice
and cells were gently scraped off the bottom of the plates with a
rubber scraper. After washing twice with culture medium, cells
were instantly subjected to staining with annexin-V
FITC and PI for
analysis of apoptosis.
Data analysis
All values obtained from electrophysiological studies represent
the mean 6 standard error of the mean (SEM). For the current-
clamp study of excitability parameters, we measured resting
membrane potential (RMP, mV), AP firing threshold (FT, mV),
rheobase (pA) and the resistance at threshold (RTh,M V). The
firing threshold was determined by differentiating the voltage trace
(dV/dt) evoked by the ramp. The voltage at which the first AP was
fired was taken as the point that exceeded the baseline value of
dV/dt by .20-fold. The baseline dV/dt was determined by
averaging the points between the onset and the following 100 ms
of the ramp. The rheobase was measured as the amount of ramp
current at the firing threshold. RTh was calculated as the FT minus
the RMP divided by the rheobase [RTh=(RMP-FT)/rheobase].
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obtained after treatment conditions were determined by using a
one-way ANOVA, or a repeated measures ANOVA (RM
ANOVA) wherever appropriate. When a significant difference
was obtained with an ANOVA, a post-hoc analysis was performed
using a Holm-Sidak all pairwise test or a Rank test. Values of
p,0.05 were judged to be significant.
Results
HIV-1 Tat protein enhanced excitability of capsaicin-
sensitive small-diameter DRG neurons
HIV-1 infection is often associated with neurological complica-
tions including cognitive deficits such as HIV-1-associated
dementia and milder forms such as cognitive/motor disorders.
Uniquely, neuronal injury, cell loss and dysfunction during HIV-1
infection occur through soluble neurotoxins rather than produc-
tive virus infection. Of these soluble neurotoxins, HIV-1 Tat has
been shown to be directly and indirectly neurotoxic in inducing
neuronal dysfunction/toxicity, resulting in CNS pathology, such as
the dementia and encephalitis associated with NeuroAIDS
[50,51]. To address whether HIV-1 Tat protein directly affects
sensory neuron function leading to HIV-1-associated pain, we
treated rat primary DRG neurons with Tat to study its effects on
DRG excitability. Heat-inactivated Tat was included as a negative
control. HIV-1 Gag protein does not elicit neurotoxicity and was
included in this study as an additional control of a viral protein
without neurotoxicity. The current-clamp configuration was used
to examine the effects of HIV-1 Tat on the capacity of sensory
neurons to fire action potentials (APs) when stimulated with a
ramp of depolarizing current over time. As shown for a
representative response (Fig. 1A), Tat, in a dose- and time-
dependent manner, increased the number of APs recorded from
small-diameter DRG neurons. While the amplitude of the ramp
was adjusted to produce 3 - 4 APs under control conditions,
exposure to 20 mM Tat for 2, 4, 6, 10 and 15 min produced 5, 6,
7, 7, and 8 APs, respectively (Fig. 1A), whereas exposure to 1 mM
Tat appeared to have no effect on AP firing (yielding 3, 3, 3, 4, and
3 APs, respectively, Fig. 1A). In contrast, 1–20 mM of Gag
treatment did not increase the number of APs when compared
with controls (data not shown). Heat-inactivated Tat (20 mM) had
no effect on the excitability of sensory neurons (Fig. 1A). The AP
results of the current-clamp experiments obtained from a total of
15 small-diameter rat primary DRG neurons are summarized in
Fig. 1B. Notably, Tat protein (20 mM) rapidly enhanced the
excitability of DRG neurons. Within 2 min of exposure, Tat
Figure 1. HIV-1 Tat enhanced excitability of small-diameter DRG neurons. Small-diameter rat primary DRG neurons were treated with HIV-1
Tat, Gag or heat-inactivated Tat, and then subjected to whole-cell patch-clamp recordings to determine action potentials (APs). (A) A representative
experiment of AP recording from one of fifteen DRG neurons is shown. The experiment was repeated at least two times. DRG neurons were exposed
to 1 mMo r2 0mM of Tat, 20 mM of Gag or 20 mM of heat-inactivated Tat, and the APs were recorded at 2 to 15 min of post-exposure to viral proteins.
Treatment with PBS was used as a control to obtain the baseline of APs. (B) Summary data from experiments performed on all fifteen DRG neurons
are shown. Bars represent SEM on the mean. Comparisons were performed between PBS and all conditions according to time points of exposure
using Anova or Repeated Measures Anova. Asterisk indicates statistically significant (*p,0.05) associations between PBS and Tat treatment according
to time points of exposure. CN: control with PBS treatment, APs: action potentials.
doi:10.1371/journal.pone.0024412.g001
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current ramp from an average control value of 2.760.5 to
4.160.3 (n=15, p,0.05). The number of APs increased with time
of Tat exposure. At the 15 min time point, the number of APs
increased to an average value of 7.360.8 when compared to the
heat-inactivated Tat control (3.560.4) or ineffective concentration
(1 mM) of Tat treatment (3.660.3). As shown in Table 1, the
increase in AP firing triggered by Tat exposure at 20 mM was
accompanied by a significant reduction in the rheobase at all time
points examined from 2 to 15 min, and by a significant increase in
RTh at the time points of 10 and 15 min, and by a significant RMP
depolarization at all time points examined from 2 to 15 min
compared to the control values (p,0.01, RM ANOVA Holm-
Sidak all pairwise test). However, Tat at 20 mM did not alter the
FT at any time point examined. Although 1 mM Tat had no effect
on AP, FT, RTh, and rheobase, this concentration of Tat produced
a significant depolarization of RMP at the 10 min time point,
suggesting that Tat at 1 mM may have a small biological effect on
DRG neurons. Exposure to heat-inactivated Tat had no effect on
parameters of DRG excitability including RMP, rheobase, FT,
and RTh at any time points examined from 2 to 15 min. To reduce
the variance of the rheobase and RTh measurements, these values
were normalized to their respective control values (Table 1). After
normalization, 20 mM Tat still showed a significant reduction in
the rheobase at all time points examined from 2 to 15 min, and a
significant increase in RTh at the time points of 10 and 15 min. In
contrast, neither 1 mM Tat nor heat-inactivated Tat had any
significant effects on the values of the rheobase or RTh over the
15 min treatment period (Table 1). These observations also
demonstrate that the recordings of neuronal excitability are stable
over this 15 min recording period. All of the small-diameter DRG
neurons tested were sensitive to capsaicin as they depolarized by at
least 5 mV and generated APs in response to capsaicin treatment
(100 nM) at the end of each recording. Therefore, these results
demonstrate that Tat causes hyperexcitability of sensory neurons,
as it triggered rapid and sustained enhancement of AP firing that
was accompanied by a significant reduction in the rheobase, an
increase in RTh, and depolarization of the RMP.
HIV-1 Tat negatively regulated Cdk5 kinase activity and
messenger RNA
Small-diameter DRG sensory neurons have central terminals in
the dorsal horn of the spinal cord and peripheral terminals in skin,
muscle, and other tissues. The hyperexcitability of these sensory
neurons leads to abnormal burst activity that could underlie the
enhanced pain sensitivity. HIV-1 Tat causes hyperexcitability of
DRG neurons, suggesting that Tat exerts a direct effect on HIV-1-
associated pain. Studies have shown that Cdk5, a proline-directed
serine/theronine kinase, is most abundant in the nervous system
including DRG neurons, and Cdk5 activity participates in the
regulation of nociceptive signaling including pain [38,39,40]. We
therefore studied whether HIV-1 Tat directly affected Cdk5 kinase
activity and mRNA production. Primary DRG neurons from rats
were treated with 20 mM of HIV-1 Tat or Gag protein for various
time intervals ranging from 15 min to 60 min. Treatment with
PBS was included to obtain the baseline of Cdk5 kinase activity
Table 1. The effect of HIV-1 Tat on parameters of DRG excitability.
Control 2 min 4 min 6 min 10 min 15 min
Tat (20 mM)
RMP (mV) 25060.8 24860.8** 24860.8** 24760.3** 24660.4** 24560.4**
FT (mV) 212.460.7 213.160.8 212.961.0 212.961.0 212.760.8 211.860.9
Rheobase (pA) 306639 252632** 246636** 219623** 207627** 213630**
Normalized rheobase 1.060 0.8460.04** 0.7960.05** 0.7560.05** 0.6960.05** 0.7060.05**
RTh (MV) 146655 162662 181681 177668 194684** 198697**
Normalized RTh 1.060 0.8460.04 0.7960.05 0.7560.05 0.6960.05** 0.7060.05**
Tat (1 mM)
RMP (mV) 25461.2 25061.1 25361.6 25661.2 24960.8* 25161.2
FT (mV) 216.361.9 218.162.0 219.762.1 217.162.1 215.761.8 216.762.1
Rheobase (pA) 388651 352658 272636 246635 229638 349663
Normalized rheobase 1.060 0.9160.08 0.7460.11 0. 6760.10 0.6560.13 0.9160.09
RTh (MV) 104610.7 105616.6 139627.7 192649.3 192649.7 114618.3
Normalized RTh 1.060 0.8460.04 0.7960.05 0.7560.05 0.6960.05 0.7060.05
Inactivated Tat (mM)
RMP (mV) 25261.0 25161.1 24961.4 25061.1 24961.1 25161.4
FT (mV) 211.961.5 212.261.8 213.461.7 211.362.0 210.662.5 29.662.8
Rheobase (pA) 392651 382649 378652 380659 373639 423648
Normalized rheobase 1.060 0.9960.06 0.9960.08 0.9960.10 1.0160.09 1.1160.06
RTh (MV) 119622 117622 106614 119621 111615 107617
Normalized RTh 1.060 0.9960.04 0.9460.07 1.0460.13 0.9960.11 0.9360.08
RMP: resting membrane potential; FT: firing threshold; RTh: resistance at threshold. Normalized rheobase: rheobase was normalized to the control. Normalized RTh:R Th
was normalized to the control. Data are expressed as mean 6 S.E.M. N=15.
*p,0.05;
**p,0.01. Groups were compared with controls by Anova or Repeated Measures Anova.
doi:10.1371/journal.pone.0024412.t001
HIV-1 Tat Affects Excitability of Sensory Neurons
PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e24412and mRNA level. We found that HIV-1 Tat rapidly inhibited
Cdk5 kinase activity as early as 15 min (Fig. 2A; 33.3% decrease).
The inhibition effect was increased by 30 min (43% decreased),
and further increased by 60 min (62% decreased). In contrast,
HIV-1 Gag had no effect on Cdk5 activity (Fig. 2A).
We next examined the effect of HIV-1 Tat on the regulation of
messenger RNA (mRNA) levels of Cdk5 and its activator p35.
DRG neurons were treated with 20 mM HIV-1 Tat, Gag or PBS
for 4 h, and then subjected to extraction of total RNA for semi-
quantitative RT-PCR and real-time qPCR assays. As shown in
Fig. 2B, a semi-quantitative RT-PCR assay revealed that Tat
markedly reduced the levels of both Cdk5 and p35 mRNAs as
compared with the PBS treatment. In contrast, treatment with
HIV-1 Gag had no effect on the levels of Cdk5 or p35 mRNAs as
compared with the PBS treatment. These results were further
confirmed by real-time qPCR analysis. As shown in Fig. 2C and
2D, HIV-1 Tat significantly reduced Cdk5 cDNA copies
(130,500637,000 cDNA copies/10
6 DRG neurons, n=3) and
p35 cDNA copies (76,09865,234 cDNA copies/10
6 DRG
neurons, n=3) as compared with PBS treatment (Cdk5:
330,800666,400 cDNA copies/10
6 DRG neurons, p35:
110,607621,230 cDNA copies/10
6 DRG neurons, n=3). In
contrast, Gag (Cdk5: 322,300672,200 cDNA copies/10
6 DRG
neurons, p35: 122,839627,256 cDNA copies/10
6 DRG neurons,
n=3) only slightly affected Cdk5 and p35 cDNA copies, which
was not statistically significant when compared with the PBS
treatment. Thus, HIV-1 Tat, but not Gag, exerts an inhibitory
effect on mRNA levels of both Cdk5 and p35.
Cdk5 inhibitor enhanced the excitability of DRG neurons
in a similar pattern to that triggered by HIV-1 Tat
To confirm that the suppression of Cdk5 kinase activity was
involved in Tat-mediated DRG hyperexcitability, we used
roscovitine (Sigma Chemical, St. Louis, MO), a potent inhibitor
of Cdk5, to treat DRG neurons and then analyze DRG
excitability. Beta-amyloid (b-amyloid)
25–35, the biologically active
and highly toxic core fragment of full-length Ab (Ab1-42), was
used as a Cdk5 activator to compare the effects of Cdk5 inhibition
and activation on DRG excitability.
We first investigated the time- and concentration-dependent
effects of the commonly used Cdk5 inhibitor roscovitine. We
found that 10 mM or higher concentration of roscovitine rapidly
enhanced the excitability of DRG neurons (Fig. 3A). Within 2 min
of exposure, roscovitine (10 mM) significantly increased the
number of APs evoked by the current ramp from an average
control value of 2.660.3 to 4.860.2 (n=5, p,0.05) (Fig. 3B). The
number of APs increased with time of roscovitine exposure to
5.260.2, 5.460.6, 6.860.2, and 8.260.5 in response to exposure
Figure 2. HIV-1 Tat inhibited endogenous Cdk5 kinase activity and mRNA production. (A) Cdk5 kinase activity in DRG neurons in response
to exposure of HIV-1 Tat or Gag. Primary DRG neurons from rats were treated with 20 mM of HIV-1 Tat or Gag for various time intervals ranging from
15 min to 60 min, and were then subjected to Cdk5 kinase assays. Treatment with PBS was included to obtain the baseline of Cdk5 kinase activity.
Open, solid gray, and solid black bars represent treatments of PBS, Tat, and Gag, respectively. Cdk5 kinase activity obtained from all conditions was
normalized to PBS-treated controls. (B), (C) and (D) Direct effects of HIV-1 Tat and Gag on the regulation of Cdk5 mRNA and p35 mRNA levels in DRG
neurons. DRG neurons were treated with 20 mM of HIV-1 Tat or Gag, or PBS for 4 h, and then subjected to analysis of Cdk5 or p35 mRNA production
using (B) semi-quantitative RT-PCR and (C) and (D) real-time qPCR assays. Bars represent SD on the mean of three individual experiments. Asterisk
indicates statistically significant (*p,0.05; **p,0.01) associations between PBS and Tat treatments.
doi:10.1371/journal.pone.0024412.g002
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respectively (Fig. 3B). As shown in Table 2, the increase in AP
firing triggered by roscovitine exposure was accompanied by a
significant reduction in the rheobase at the time points of 6 min,
10 min and 15 min and an increase in RTh at the time points of
10 min and 15 min. To reduce the variance between the neurons,
the rheobase and RTh were normalized to their respective control
values, these results are summarized in Table 2. Similar to Tat,
roscovitine produced a significant depolarization of the RMP with
no change in the FT (Tables 1 and 2). In contrast, treatment with
Figure 3. Inhibition of Cdk5 kinase activity enhanced the excitability of DRG neurons. Small-diameter rat primary DRG neurons were
treated with Cdk5 inhibitor roscovitine (10 mM) or activator b-amyloid (10 mM), and then subjected to whole-cell patch-clamp recordings to
determine action potentials (APs). (A) A representative experiment of AP recording from one of seven DRG neurons is shown. (B) Summary data from
experiments performed on all seven DRG neurons are shown. Bars represent SEM on the mean. Comparisons were performed between PBS and
roscovitine or b-amyloid according to time points of exposure using Anova or Repeated Measures Anova. Asterisk indicates statistically significant
(p,0.05) associations between PBS and roscovitine or b-amyloid according to time points of exposure. CN: control with PBS treatment, APs: action
potentials.
doi:10.1371/journal.pone.0024412.g003
Table 2. The effect of Cdk5 inhibitor or activator on parameters of DRG excitability.
Control 2 min 4 min 6 min 10 min 15 min
Roscovitine
RMP (mV) 25261.3 25161.8 -4762.4** 24662.1** 24462.0** 24361.4**
FT (mV) 213.860.9 212.961.1 213.460.8 212.962.9 213.361.6 211.961.3
Rheobase (pA) 209626 202628 181625 131625** 92618** 77614**
Normalized rheobase 1.060 0.9560.03 0.8660.04* 0.6260.07** 0.4360.05** 0.3660.04**
RTh (MV) 199622 209626 202624 292643 383650** 458658**
Normalized RTh 1.060 1.0460.03 1.0260.05 1.4960.21 1.9360.20** 2.3360.25**
ß-Amyloid
RMP (mV) 25160.5 25062.4 25061.5 25262.8 24961.4 24961.1
FT (mV) 212.361.9 213.061.4 213.161.8 211.361.7 211.861.8 213.462.0
Rheobase (pA) 276638 268647 286633 290630 299636 307643
Normalized rheobase 1.060 0.9560.04 1.0860.13 1.1060.14 1.1260.12 1.1560.13
RTh (MV) 153625 153623 135614 148621 130614 126617
Normalized RTh 1.060 1.0260.08 0.9460.11 1.0160.13 0.8960.09 0.8660.11
RMP: resting membrane potential; FT: firing threshold; RTh: resistance at threshold. Normalized rheobase: rheobase was normalized to the control. Normalized RTh:R Th
was normalized to the control. Data are expressed as mean 6 S.E.M. N=7.
*p,0.05;
**p,0.01. Groups were compared with controls by Anova or Repeated Measures Anova.
doi:10.1371/journal.pone.0024412.t002
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the rheobase, or RTh over the 15 min recording period (Table 2).
Thus, only the inhibitor of Cdk5, roscovitine, affected neuronal
excitability. Notably, roscovitine causes DRG hyperexcitability in
a very similar pattern to those triggered by Tat, suggesting Tat
may use this signaling pathway to cause HIV-1 associated pain.
Tat-mediated increase of AP and depolarization of RMP
were not affected by roscovitine
Tat caused DRG hyperexcitability in a very similar pattern to
that triggered by Cdk5 inhibitor roscovitine, suggesting that Tat
and roscovitine may affect bioactivity of DRG neurons via the
same or overlapping intracellular pathways. To test this possibility,
20 mM Tat was focally applied to individual neurons for an
exposure time of 4 min. At this point the neuron was additionally
exposed to 10 mM roscovitine by bath perfusion. A representative
experiment (Fig. 4A) and summary data from 5 small-diameter rat
primary DRG neurons (Fig. 4B) demonstrated that Tat-mediated
increase of AP was not affected by subsequent addition of
roscovitine. Similarly, Tat-mediated depolarization of RMP was
not affected by roscovitine (Fig. 5 and Table 3), as Tat plus
roscovitine treatment depolarized RMP to -46.4 6 2.2 (n=5),
244.4 6 2.7 (n=5), and 244.0 6 3.3 (n=5) at the time points of
6 min, 10 min, and 15 min, respectively, which were not different
for the depolarization of RMP produced by Tat alone at these
time points (6 min: 246.6 6 0.3, n=15, p=0.72 t-test; 10 min:
245.8 6 0.4, n=15, p=0.05 t-test, and 15 min: 245.1 6 0.4,
n=15, p=0.20 t-test) (Fig. 5 and Table 3). However, roscovitine
significantly accelerated the effects of Tat on the rheobase and RTh
(Fig. 5 and Table 3). Tat plus roscovitine significantly reduced the
normalized value of the rheobase further to 0.54 6 0.04 (n=5),
0.48 6 0.06 (n=5), and 0.46 6 0.04 (n=5) at the time points of
6 min, 10 min, and 15 min, respectively, when compared with
that produced by Tat alone at these time points (6 min: 0.75 6
0.05, n=15, p,0.01 t-test; 10 min: 0.69 6 0.05, n=15, p,0.01 t-
test, and 15 min: 0.70 6 0.05, n=15, p,0.01 t-test) (Fig. 5 and
Table 3). Meanwhile, Tat plus roscovitine significantly increased
the normalized value of RTh further to 1.47 6 0.08 (n=5), 1.65 6
0.16 (n=5), 1.68 6 0.24 (n=5) at the time points of 6 min,
10 min, and 15 min, respectively, when compared with that
produced by Tat alone at these time points (6 min: 1.25 6 0.09,
n=15, p,0.01 t-test; 10 min: 1.37 6 0.11, n=15, p,0.01 t-test,
and 15 min: 1.37 6 0.13, n=15, p,0.01 t-test) (Fig. 5 and
Table 3). Thus, these results demonstrate that Tat-mediated
increase of AP and depolarization of RMP were not affected by
roscovitine, but the effects of Tat on the rheobase or RTh were
accelerated by roscovitine, suggesting that Tat-mediated changes
in DRG excitability are partly facilitated by Cdk5 inhibition.
HIV-1 Tat induced apoptosis of DRG neurons
HIV-1 Tat has been implicated in inducing apoptosis of
neurons in the CNS. To determine whether HIV-1 Tat also
induces apoptosis in rat DRG neurons, we exposed isolated
neurons to 20 mM Tat for 30 min to 72 h and then assessed the
extent of apoptosis by Annexin-V staining and flow cytometric
analysis. Treatment with 20 mM HIV-1 Gag was performed as a
control. Treatment with HIV-1 Tat for longer than 48 h induced
DRG morphology changes and apoptosis (Fig 6A, 6B and 6C)
whereas exposure for less than 48 h only enhanced apoptosis
slightly, but did not show a significant difference when compared
to PBS treatment (data not shown). In contrast, HIV-1 Gag did
not affect rat DRG survival as annexin staining results did not
change when compared with that of PBS-treated DRG neurons
(Fig 6A, 6B and 6C). These findings also correlated with viable cell
counts, as determined by trypan blue exclusion (data not shown).
Therefore, chronic exposure of HIV-1 Tat triggers apoptosis of
DRG neurons in vitro.
Discussion
Small-diameter DRG neurons have central terminals in the
spinal cord dorsal horn and peripheral terminals in skin, muscle,
Figure 4. Tat-mediated increase of AP and depolarization of RMP were not affected by roscovitine. Tat at 20 mM was focally applied to
an individual DRG neuron to assess its actions over a 4 min time period, thereafter, the neuron was exposed to 10 mM roscovitine by external
perfusion of the recording chamber. The whole-cell patch-clamp recordings were used to determine APs prior to Tat exposure (control), exposure to
Tat or roscovitine or both. (A) A representative experiment of AP recording from one of five DRG neurons is shown. (B) Summary data from time
points of Tat alone (n=15) and Tat plus roscovitine co-exposure performed on all five DRG neurons are shown. Bars represent SEM on the mean. Ros:
roscovitine, APs: action potentials.
doi:10.1371/journal.pone.0024412.g004
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relay pain-related signals and temperature sensation from
peripheral tissues to the spinal cord and brain. Neurotoxins and
inflammatory molecules can cause hyperexcitability of DRG
neurons leading to spontaneous or persistent firing. These agents
can also induce apoptosis of DRG neurons, resulting in permanent
neuron damage, death, and even nerve lesions. It is well
established that peripheral sensitization of primary DRG neurons
is the key event in the onset of chronic pain conditions [52].
Peripheral sensitization is defined as the enhancement of a
baseline response, such as AP firing, after exposure to a defined
mediator [52]. For example, exposure to the pro-inflammatory
prostaglandin E2 (PGE2), increases the number of APs evoked by
an excitatory stimulus by about three-fold compared to the
control, thus the neuronal output is intensified by PGE2 [53,54].
This increased firing is believed to be critical in the enhanced
perception of pain sensation for both inflammatory and neuro-
pathic conditions [53,54]. Several HIV-1 proteins, in particular
Tat, exhibit neurotoxic properties and therefore may directly
impact excitability and survival of small-diameter DRG neurons,
leading to HIV-1-associated pain. In this study, we show that
HIV-1 Tat, but not Gag or heat-inactivated Tat, triggers rapid
and sustained enhancement of the excitability of small-diameter
rat primary DRG neurons. The Tat-mediated increase in DRG
excitability was accompanied by marked reductions in the
rheobase and RMP, and an increase in RTh. This Tat-mediated
Table 3. Comparison of parameters of DRG excitability between treatments of Tat alone verse Tat then roscovitine.
Control 2 min 4 min 6 min 10 min 15 min
Tat (20 mM) + + + + +
Roscovitine (10 mM) + (2 min) + (6 min) + (11 min)
RMP (mV) 25361.3 25061.6 25062.8 24662.2** 24462.7** 24463.3**
FT (mV) 214.661.8 215.062.2 214.362.3 215.662.3 215.161.6 214.962.1
Rheobase (pA) 348666 281652 219646** 179625** 154620** 152620**
Normalized rheobase 1.060 0.8260.04** 0.6360.06** 0.5460.04** 0.4860.06** 0.4660.04**
RTh (MV) 125622 148635 184635 186639 208647 222670**
Normalized RTh 1.060 1.1360.09 1.4560.05 1.47608 1.6560.16** 1.6860.24**
RMP: resting membrane potential; FT: firing threshold; RTh: resistance at threshold. Normalized rheobase: rheobase was normalized to the control. Normalized RTh:R Th
was normalized to the control. Data are expressed as mean 6 S.E.M. N=5.
*p,0.05;
**p,0.01. Groups were compared with controls by Anova or Repeated Measures Anova.
doi:10.1371/journal.pone.0024412.t003
Figure 5. Comparison of parameters of DRG excitability between treatments of Tat alone verse Tat then roscovitine. Parameters of
DRG excitability including RMP, FT, Rheobase and RTh were compared between groups of Tat treatment alone versus Tat pretreatment followed by
roscovitine exposure. The rheobase and RTh were normalized to their respective control values. Bars represent SEM on the mean. Asterisk indicates
statistically significant (*p,0.05; **p,0.01) associations between the two groups at the same time point using Student T-test. Open bars: Tat alone,
solid gray bars: Tat plus roscovitine. Ros: roscovitine, APs: action potentials, RMP: resting membrane potential; FT: firing threshold; and RTh: resistance
at threshold.
doi:10.1371/journal.pone.0024412.g005
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role in the initiation of HIV-1-associated pain, particularly during
the early stages of the viral infection because (1) HIV-1-associated
pain occurs even before severe neuronal injury and death. Pain
has been described at all stages of HIV-1 infection, although its
severity and frequency correlate with disease progression [1,13].
Severe neuronal injury and death generally occurs in later or
advanced stages of HIV-1 infection, and thus is unlikely to be
responsible for pain during the early stages of viral infection. (2)
Patients in the early stages usually have not yet received ART, and
therefore have high levels of HIV-1 proteins in their circulations
due to the burst of rapid viral replication and of viral protein
secretion. In the early stages of HIV-1 infection, viral loads in both
plasma and cerebrospinal fluid (CSF) are very high, commonly
approaching several million viruses per mL [55,56].
The concentration of Tat required to induce hyperexcitability of
DRG neurons in this study is much higher than that in the sera of
HIV-1 patients. Soluble Tat levels in the sera of HIV-1-infected
patients have been measured up to 40 ng/ml (, 30 nM) [57,58].
However, Tat concentrations surrounding HIV-infected cells are
much higher than sera concentrations because the interactions of
Tat with endogenous glycosaminoglycans and heparin sulfates
lower measurable Tat concentration in vivo [58,59,60]. In addition,
genetically engineered recombinant Tat is considerably less potent
than Tat released from infected cells, suggesting that compara-
tively higher doses of the recombinant Tat are required to
adequately mimic the effects of Tat released from HIV-1-infected
cells [35]. Moreover, human sensory neurons may be more
sensitive to Tat than that of rats, making it possible that a lower
concentration of Tat may induce excitability of human sensory
neurons. Finally, in the context of HIV-1 infection, the effects of
Tat may occur over long-term chronic low-dose exposure.
Therefore, our data must be validated by in-vivo studies such as
injection of Tat into the spinal intrathecal space of rats to study
pain-like behavior.
Tat also triggered apoptosis of DRG neurons in a pattern of
chronic exposure, which is in accordance with the chronic effects
of HIV-1 infection on nerve degeneration. Such chronic effects of
Tat on survival of DRG neurons may contribute to neuronal
injury and death in late or advanced stages of HIV-1 infection,
resulting in more severe and frequent of pain with disease
progression. Thus, HIV-1 Tat may be involved in pain at all stages
of HIV-1 infection, i.e. the rapid onset of DRG hyperexcitability
triggered by Tat may be mainly responsible to pain at very early
stages of HIV-1 infection, whereas Tat-mediated chronic apop-
tosis of sensory neurons causes and accelerates pain in the
advanced stages of the disease.
Previous reports have demonstrated that Cdk5, a proline-
directed serine/threonine kinase, is most abundant in DRG and
other neurons, and its kinase activity and protein expression can
be altered in response to peripheral inflammation, resulting in
enhancement of pain signaling [38,39,40]. We thus speculated that
Tat might mediate DRG hyperexcitability by regulating Cdk5
kinase activity. We found that HIV-1 Tat caused an immediate
inhibition of Cdk5 kinase activity and down-regulation of Cdk5
mRNA production, whereas HIV-1 Gag had no effects. In
addition, we found that Tat also inhibited p35 (an activator of
Cdk5) mRNA production in DRG neurons, which is in agreement
Figure 6. DRG neurons underwent apoptosis in response to chronic exposure of HIV-1 Tat. Rat primary DRG neurons were exposed to
20 mM of HIV-1 Tat or Gag for 30 min to 72 h, and were then subjected to apoptosis analysis by Annexin-V staining and flow cytometric analysis. (A)
DRG morphological changes in response to exposure of HIV-1 proteins for 48 h. (B) A representative annexin-v staining of DRG apoptosis in response
to exposure of HIV-1 Tat or Gag for 48 h. Solid gray histogram represents a staining control without adding annexin-V
FITC, whereas histograms with
blue, green, and red lines represent annexin-V staining on DRG neurons treated with PBS, Gag, and Tat, respectively. (C) Summary data from three
independent experiments of annexin-V staining on DRG neurons in response to exposure of HIV-1 Tat and Gag for 48 h or 72 h are shown. Bars
represent SD on the mean of three individual experiments. Asterisk indicates statistically significant (p,0.05) associations between PBS and Tat or
Gag according to time points of exposure.
doi:10.1371/journal.pone.0024412.g006
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to inhibit Cdk5 activity, i.e., directly inhibits Cdk5 kinase activity
and its mRNA production and indirectly inhibits Cdk5 activity by
suppressing Cdk5 activator p35 mRNA production. However,
Tat-mediated DRG hyperexcitability may be related to direct
inhibition of Cdk5 kinase activity rather than suppression of Cdk5
and p35 mRNA or protein production because of the rapid onset
of DRG hyperexcitability in response to Tat treatment. Rapid
Cdk5 inhibition upon HIV-1 Tat treatment was coupled with
rapid DRG hyperexcitability, which suggested that there might be
a relationship between the two events. To investigate this
relationship, we used roscovitine, a potent inhibitor of Cdk5, to
treat DRG neurons. We also used b-amyloid, a biological activator
of Cdk5, as a control to compare the effects of a Cdk5 inhibitor
and activator on DRG excitability. We found that b-amyloid did
not affect DRG excitability. In contrast, roscovitine induced a very
similar pattern of DRG hyperexcitability to that triggered by Tat:
an immediate increase of AP numbers, which was accompanied by
marked reductions in the rheobase and RMP, and an increase in
RTh. Furthermore, pre-application of Tat prevented roscovitine
from having additional effects on the RMP and APs. These results
suggest that Tat-mediated hyperexcitability of DRGs may be
facilitated by Cdk5 inhibition. However, the effects of Tat on the
rheobase and RTh were accelerated by roscovitine, indicating that
the intracellular pathways affected by Tat and roscovitine may not
fully overlap. It is also possible that roscovitine accelerated the
effects of Tat on the rheobase and RTh by its side effects, as this
chemical compound is also a potent inhibitor of CDK2 and other
kinases [63]. We are currently studying the molecular mechanisms
of Tat-mediated suppression of Cdk5 kinase activity and gene
expression.
Cdk5 has recently emerged as an essential kinase in sensory
pathways and its activity is tightly regulated. Previous studies have
shown that p35-overexpressing transgenic mice, with elevated
levels of Cdk5 activity are hypersensitive to painful thermal stimuli
[38,39,40]. In contrast, our data using HIV-1 Tat protein revealed
that aberrant inhibition of Cdk5 activity triggers pain signaling.
Furthermore, elevated levels of Cdk5 activity have been associated
with an increase of apoptosis in cultured neuronal cells [64]. We
show that Cdk5 inhibition also promotes apoptosis of DRG
neurons. These distinct results reveal that both aberrant activation
or inhibition of Cdk5 signaling can promote pain signaling and
neuronal cell death, indicating Cdk5 as a master switch controlling
neuronal survival and death [65,66,67,68]. Thus, basal Cdk5
activity is important for maintaining normal functions and survival
of DRG neurons.
Tat and gp120 can be actively released by HIV-1-infected cells
into the circulating blood stream, the extracellular space, and
cerebrospinal fluid (CSF) [50,59,69,70]. These two viral proteins
have been demonstrated to directly induce apoptosis of neurons in
the CNS, possibly through different mechanisms. Soluble HIV-1
gp120 can bind CXCR4, CCR5 and/or others on neurons in the
absence of CD4 [71,72,73,74]. The lethal signal transduction may
involve a number of kinases, transcription factors, and typical
ingredients of the mitochondrial apoptotic cascade [72]. Some of
these mechanisms may also be used by gp120 to induce apoptosis
of sensory neurons including DRGs [31,75,76]. HIV-1 Tat
induces apoptosis of neurons [77,78,79,80,81,82,83,84], however,
by binding to the low-density lipoprotein receptor-related protein
(LRP) with subsequent activation of the Ca
2+-permeable NMDA
receptor (NMDAR) [37,85]. Activation of NMDAR allows the
flow of Ca
2+ and other ions into the cells, resulting in activation of
neuronal nitric oxide synthase (nNOS) causing cell apoptosis
[37,85,86]. Recent studies also demonstrate that Tat directly binds
to NMDAR leading to excitotoxicity [34,36,87,88,89,90]. The
HIV-1 Tat protein is an 86 – 101 amino acid (aa) protein encoded
by two exons. The most functional properties of Tat are attributed
to Tat 1-72 encoded by exon 1. Tat 1-72 has an essential cysteine
(Cys) rich region that mediates the interaction of NMDAR [35].
This Cys-rich region contains a Cys30-Cys31 motif that is critical
for exciting the NMDAR as the mutation of Cys31 significantly
attenuate Tat neurotoxicity [35]. Interestingly, Cdk5 and the
NMDAR are known to physically and functionally associate with
each other, as (1) anti-Cdk5 antibodies coprecipitate NMDAR
from brain extracts [91], indicating that the two proteins bind to
each other, and (2) Cdk5 kinase has been shown to direct or
indirectly modulate NMDAR function by phosphorylating the
long tail of an NMDAR subunit [92,93]. Here, we demonstrate for
the first time that HIV-1 Tat induces hyperexcitability and
apoptosis of DRG neurons, probably by inhibiting Cdk5 kinase
activity and protein expression. Thus, it will be exciting to
determine which region or motif of Tat mediates DRG
neurotoxicity and whether Tat exerts its neurotoxicity through a
chain reaction of NMDAR-Cdk5 interaction.
Taken together, our study demonstrates that HIV-1 Tat causes
hyperexcitability and apoptosis of DRG neurons, probably by
inhibiting Cdk5 kinase activity and protein expression. Tat-
mediated hyperexcitability of DRG neurons may play a key role in
the initiation of HIV-1-associated pain in patients at the early
stages of the viral infection. HIV-1 Tat and other proteins induce
apoptosis of DRG neurons, which may be involved in HIV-1-
associated pain at all stages of viral infection. This study has
potentially important implications for developing therapeutic
strategies to prevent or treat HIV-1-assciated pain. For example,
early initiation of HAART and/or neutralization of HIV-1 protein
neurotoxicity may significantly prevent or delay HIV-1-associated
pain. A recent study using a simian immunodeficiency virus (SIV)-
macaque model of HAART demonstrates that early initiation of
HAART results in a dramatic reduction of viral RNA levels in
plasma, CSF and brain [94], suggesting that early initiation of
HAART can reduce or delay neurological complications including
pain in HIV-1-infected patients.
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